Roanna Ruiz
Stock Analyst at Leerink Partners
(0.60)
# 3,806
Out of 4,735 analysts
59
Total ratings
25%
Success rate
-21.03%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $10.42 | +91.94% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $13.48 | +100.30% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.21 | +304.98% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $4.91 | +185.13% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $367.97 | -10.32% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $45.82 | +26.58% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $61.11 | -59.09% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $5.12 | +857.03% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $3.34 | +49.70% | 4 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $3.24 | +301.23% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.24 | +85.19% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $23.70 | -19.83% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $94.05 | +27.59% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $33.79 | +47.97% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $2 | $0.57 | +251.12% | 6 | Oct 19, 2022 |
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $10.42
Upside: +91.94%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $13.48
Upside: +100.30%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.21
Upside: +304.98%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $4.91
Upside: +185.13%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $367.97
Upside: -10.32%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $45.82
Upside: +26.58%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $61.11
Upside: -59.09%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $5.12
Upside: +857.03%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $3.34
Upside: +49.70%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $3.24
Upside: +301.23%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.24
Upside: +85.19%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $23.70
Upside: -19.83%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $94.05
Upside: +27.59%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $33.79
Upside: +47.97%
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.57
Upside: +251.12%